These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 15069581

  • 1. Development of an optimal sampling strategy for clinical pharmacokinetic studies of the novel anthracycline disaccharide analogue MEN-10755.
    Bos AM, Boom K, Vinks AA, Boezen HM, Wanders J, Dombernovsky P, Aamdal S, de Vries EG, Uges DR.
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):64-70. PubMed ID: 15069581
    [Abstract] [Full Text] [Related]

  • 2. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R.
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [Abstract] [Full Text] [Related]

  • 3. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
    Langers P, Cremers SC, den Hartigh J, Rijnbeek EM, Ringers J, Lamers CB, van Hoek B.
    Aliment Pharmacol Ther; 2005 Mar 01; 21(5):549-57. PubMed ID: 15740538
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
    Delattre IK, Musuamba FT, Nyberg J, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq PE.
    Ther Drug Monit; 2010 Dec 01; 32(6):749-56. PubMed ID: 20962708
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M, Huitema AD, Meenhorst PL, Schellens JH, Beijnen JH.
    Cancer Chemother Pharmacol; 2005 May 01; 55(5):488-96. PubMed ID: 15726371
    [Abstract] [Full Text] [Related]

  • 6. An evaluation of an optimal sampling strategy for meropenem in febrile neutropenics.
    Ariano RE, Zelenitsky SA, Nyhlén A, Sitar DS.
    J Clin Pharmacol; 2005 Jul 01; 45(7):832-5. PubMed ID: 15951473
    [Abstract] [Full Text] [Related]

  • 7. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.
    Schoemaker NE, Mathôt RA, Schöffski P, Rosing H, Schellens JH, Beijnen JH.
    Cancer Chemother Pharmacol; 2002 Dec 01; 50(6):514-7. PubMed ID: 12451480
    [Abstract] [Full Text] [Related]

  • 8. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia.
    Plard C, Bressolle F, Fakhoury M, Zhang D, Yacouben K, Rieutord A, Jacqz-Aigrain E.
    Cancer Chemother Pharmacol; 2007 Sep 01; 60(4):609-20. PubMed ID: 17195068
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH, Schiere S, Eleveld DJ, Wierda JM.
    Biopharm Drug Dispos; 2007 Nov 01; 28(8):455-73. PubMed ID: 17847121
    [Abstract] [Full Text] [Related]

  • 10. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.
    Salinger DH, Vicini P, Blough DK, O'Donnell PV, Pawlikowski MA, McCune JS.
    J Clin Pharmacol; 2010 Nov 01; 50(11):1292-300. PubMed ID: 20075185
    [Abstract] [Full Text] [Related]

  • 11. Population pharmacokinetics of ciprofloxacin in patients with liver impairments analyzed by NPEM2 algorithm--a retrospective study.
    Terziivanov D, Atanasova I, Dimitrova V.
    Int J Clin Pharmacol Ther; 1998 Jul 01; 36(7):376-82. PubMed ID: 9707352
    [Abstract] [Full Text] [Related]

  • 12. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
    Huitema AD, Mathôt RA, Tibben MM, Schellens JH, Rodenhuis S, Beijnen JH.
    Clin Pharmacol Ther; 2000 Jun 01; 67(6):621-30. PubMed ID: 10872644
    [Abstract] [Full Text] [Related]

  • 13. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus.
    Uges JW, van Huizen MD, Engelsman J, Wilms EB, Touw DJ, Peeters E, Vecht CJ.
    Epilepsia; 2009 Mar 01; 50(3):415-21. PubMed ID: 19054418
    [Abstract] [Full Text] [Related]

  • 14. The effect of age on the early disposition of doxorubicin.
    Li J, Gwilt PR.
    Cancer Chemother Pharmacol; 2003 May 01; 51(5):395-402. PubMed ID: 12679882
    [Abstract] [Full Text] [Related]

  • 15. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H, Mayer PR, Wajdula J, Fatenejad S.
    J Clin Pharmacol; 2004 Nov 01; 44(11):1235-43. PubMed ID: 15496641
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE, Chaudhary A, Ghosh A, Johnson RD.
    Cancer Chemother Pharmacol; 2006 Apr 01; 57(4):401-11. PubMed ID: 16322991
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis.
    Mahmood I, Miller R.
    Int J Clin Pharmacol Ther; 1999 Sep 01; 37(9):439-45. PubMed ID: 10507242
    [Abstract] [Full Text] [Related]

  • 18. Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method.
    Wang J, Liang WQ, Wu JJ, Pan CM.
    Acta Pharmacol Sin; 2000 Oct 01; 21(10):954-60. PubMed ID: 11501052
    [Abstract] [Full Text] [Related]

  • 19. Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children.
    Turner PK, Iacono LC, Panetta JC, Santana VM, Daw NC, Gajjar A, Stewart CF.
    Cancer Chemother Pharmacol; 2006 Apr 01; 57(4):475-82. PubMed ID: 16047146
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model.
    Munck JN, Riggi M, Rougier P, Chabot GG, Ramirez LH, Zhao Z, Bognel C, Ardouin P, Herait P, Gouyette A.
    Cancer Res; 1993 Apr 01; 53(7):1550-4. PubMed ID: 8453622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.